Unbiased Analysis of Today's Healthcare Issues
Performance-based risk sharing (PBRS) have grown in importance in recent years. While most PBRS are used for expensive pharmaceutical products, PBRS also have been used with medical device and diagnostic manufacturers. Device/diagnostic PBRS may differ from those of pharmaceuticals for a number of reasons. First, while health insurers bear the burden of paying for most…
That is the topic of a recent paper by Augustovski et al. (2021). The authors conduct a targeted literature review of previous diagnostics value frameworks in other countries. A full list of these articles is below. Then the researchers pool the criteria and created a proposed value framework. A panel of experts was then met…
When evaluating a new diagnostic, HTA agencies must assess two separate issues: analytical and clinical validity. Analytical validity basically indicates whether the test works; is it able to accurately predicts the presence or absence of a particular biomarker of interest. Clinical validity is whether the test matters in clinical practice. It could be the case…
Precision medicine is the future…at least that is what we have been told. But to treat patients based on genetic biomarkers, one first has to test for these biomarkers. What factors to payers consider when evaluating whether or not they should provide coverage for these genetic tests? This is the exact question that Dhanda et…
With co-authors Katalin Bognar, Michelle Brauer, Lauren Zhao, Rick Hockett, Michael O’Neil and Anupam Jena, I am excited to announce that our study “The potential value of rapid, cloud-enabled onsite testing for the diagnosis of rheumatoid arthritis in the United States” was published in the Journal of Medical Economics today. The full abstract is below. …